Insulin-like Growth Factor II mRNA-Binding Protein 3 Expression in Benign and Premalignant Lesions and Carcinomas of the Stomach
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Recent studies have demonstrated that insulin-like growth factor II mRNA-binding protein 3 (IMP3) is expressed in malignant tumors of various organs but not in normal tissue. We investigated IMP3 expression in various benign lesions, premalignant lesions and carcinomas of the stomach. Methods: IMP3 immunohistochemical staining was performed on 24 benign gastric lesions, 24 gastric adenomas, and 322 gastric carcinomas. Results: IMP3 was not expressed in benign gastric lesions including adenomas with low-grade dysplasia, but was expressed in 17% of adenomas with high-grade dysplasia, and in 44% of carcinomas. As the carcinomas were in the advanced stage, they expressed IMP3 more frequently and strongly. Patients with IMP3-positive tumors had poorer survival than those with negative tumors. Conclusions: IMP3 expression in gastric carcinoma may be related to tumor invasion and metastasis, and is an independent risk factor for poor prognosis.
Abstract
Background: Recent studies have demonstrated that insulin-like growth factor II mRNA-binding protein 3 (IMP3) is expressed in malignant tumors of various organs but not in normal tissue. We investigated IMP3 expression in various benign lesions, premalignant lesions and carcinomas of the stomach. Methods: IMP3 immunohistochemical staining was performed on 24 benign gastric lesions, 24 gastric adenomas, and 322 gastric carcinomas. Results: IMP3 was not expressed in benign gastric lesions including adenomas with low-grade dysplasia, but was expressed in 17% of adenomas with high-grade dysplasia, and in 44% of carcinomas. As the carcinomas were in the advanced stage, they expressed IMP3 more frequently and strongly. Patients with IMP3-positive tumors had poorer survival than those with negative tumors. Conclusions: IMP3 expression in gastric carcinoma may be related to tumor invasion and metastasis, and is an independent risk factor for poor prognosis.
참고문헌 (27)
- Nielsen J, "A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development", Mol Cell Biol, 19, pp.1262~1270 (1999)
- Mueller-Pillasch F, "Expression of the highly conserved RNA binding protein KOC in embryogenesis", Mech Dev, 88, pp.95~99 (1999)
- Monk D, "Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome", J Med Genet, 39, pp.575~581 (2002)
- Müeller-Pillasch F, "Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein", Oncogene, 14, pp.2729~2733 (1997)
- Burd CG, "Conserved structures and diversity of functions of RNA-binding proteins", Science, 265, pp.615~621 (1994)
- 이정희, "세포병리검사에서 쓸개관암종의 IMP3 발현과 진단적 가치", The Korean Journal of Pathology, 44(6), pp.642~650 (2010), 대한병리학회
- Li D, "IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis", Ann Surg Oncol, 16, pp.3499~3506 (2009)
- Jeng YM, "RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma", Hepatology, 48, pp.1118~1127 (2008)
- Bellezza G, "IMP3 expression in non-small cell lung cancer", Hum Pathol, 40, pp.1205~1206 (2009)
- Walter O, "IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype", Hum Pathol, 40, pp.1528~1533 (2009)
- Jiang Z, "Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study", Lancet Oncol, 7, pp.556~564 (2006)
- Schaeffer DF, "Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival", BMC Cancer, 10, pp.59~ (2010)
- 원영주, "Nationwide Cancer Incidence in Korea, 2003~2005", Cancer Research and Treatment, 41(3), pp.122~131 (2009), 대한암학회
- Sakuramoto S, "Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine", N Engl J Med, 357, pp.1810~1820 (2007)
- Rogers WM, "Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications", Am J Surg Pathol, 32, pp.799~809 (2008)
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376(9742), pp.687~697 (2010), ELSEVIER SCIENCE INC
- Guo R, "p53 and vascular endothelial growth factor expressions are two important indices for prognosis in gastric carcinoma", West Indian Med J, 57, pp.2~6 (2008)
- Lee HE, "Low Ki-67 Proliferation Index Is an Indicator of Poor Prognosis in Gastric Cancer", JOURNAL OF SURGICAL ONCOLOGY, 102, pp.201~206 (2010), WILEY-LISS
- Czyzewska J, "Immunohistochemical evaluation of Ki-67, PCNA and MCM2 proteins proliferation index (PI) in advanced gastric cancer", Folia Histochem Cytobiol, 47, pp.289~296 (2009)
- Danesi DT, "Flow cytometric DNA ploidy, p53, PCNA, and c-erbB-2 protein expressions as predictors of survival in surgically resected gastric cancer patients", Cytometry, 42, pp.27~34 (2000)
- Jeng YM, "Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma", Br J Surg, 96, pp.66~73 (2009)
- Bosman FT, "WHO classification of tumours of the digestive system. 4th ed", pp.52~53 (2010), IARC Press
- Lauren P, "The Two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification", Acta Pathol Microbiol Scand, 64, pp.31~49 (1965)
- Greene FL, "AJCC cancer staging manual. 6th ed", pp.99~103 (2002), Springer-Verlag
- Yaniv K, "The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis", Gene, 287, pp.49~54 (2002)
- Vikesaa J, "RNA-binding IMPs promote cell adhesion and invadopodia formation", EMBO J, 25, pp.1456~1468 (2006)
- Nemunaitis J, "Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer", Mol Ther, 13, pp.1185~1191 (2006)